Home > Clinical Trials
Check All Search

Saved trials

NOT_YET_RECRUITING
NCT07198724
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
65 Enrollment(s)
2 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Metastatic Breast Cancer


HER2 Low Breast Carcinoma


HER2-negative Breast Cancer


Breast Cancer


Breast Cancer Female
RECRUITING
NCT07025148
Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)
40 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Coronary Arterial Disease (CAD)


Percutaneous Coronary Intervention (PCI)
WITHDRAWN
NCT04684212
Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF
0 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (NA)
Atrial Fibrillation


Left Atrial Appendage Thrombosis


CVA
NOT_YET_RECRUITING
NCT07022483
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
710 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE3)
Endometrial Cancer
RECRUITING
NCT05950945
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
250 Enrollment(s)
84 Study location(s)
INTERVENTIONAL (PHASE3)
Breast Cancer
COMPLETED
NCT05103332
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
663 Enrollment(s)
110 Study location(s)
INTERVENTIONAL (PHASE2)
Hypertension
SUSPENDED
NCT04616560
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
77 Enrollment(s)
28 Study location(s)
INTERVENTIONAL (PHASE2)
Osteosarcoma


Recurrent Osteosarcoma
RECRUITING
NCT04128748
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
52 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Acute Myeloid Leukemia


Blasts More Than 10 Percent of Bone Marrow Nucleated Cells


High Risk Myelodysplastic Syndrome


Recurrent Acute Myeloid Leukemia


Recurrent Myelodysplastic Syndrome


Refractory Acute Myeloid Leukemia


Refractory Myelodysplastic Syndrome